Athernal Bio
PrivateLast Round
Seed
Oct 1, 2025
Total Funding Raised
$4.72M
Company Overview
Athernal Bio is a biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition, with the goal of preventing cancer before it starts.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Athernal Bio Comps
Public and private peers based on sector, stage, and business model.
Athernal Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 1, 2025 |
Key People
Founding team and executive leadership
Athernal Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Delin Ventures | Seed |
Athernal Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Athernal Bio's valuation, stock price, and market status.
